Nuvalent (NUVL): Assessing an Expensive-Looking Valuation After a Strong Multi-Year Share Price Run [Yahoo! Finance]
Nuvalent to Present at the 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]
Nuvalent to Present at the 44th Annual J.P. Morgan Healthcare Conference
Nuvalent (NASDAQ:NUVL) had its price target lowered by analysts at JPMorgan Chase & Co. from $147.00 to $145.00. They now have an "overweight" rating on the stock.
Nuvalent (NASDAQ:NUVL) had its "buy" rating reaffirmed by analysts at UBS Group AG.